Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Sponsor: Hoffmann-La Roche
Summary
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.
Official title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-06-25
Completion Date
2028-04-02
Last Updated
2026-06-26
Healthy Volunteers
No
Interventions
Enicepatide
Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.
Placebo
Participants will receive matching placebo via SC injection as per the schedule in the protocol.
Locations (3)
The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)
Ningbo, Zhejiang, China
Peking University People's Hospital
Beijing, China
Shanghai Fifth People's Hospital Affiliated to Fudan University
Shanghai, China